Anbio Biotechnology: basic weighted-average shares
Basic weighted-average shares for Anbio Biotechnology. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Anbio Biotechnology financial histories
What this measure means
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
Exact concept: us-gaap:WeightedAverageNumberOfSharesOutstandingBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2022-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 43,672,022 | shares | 2026-04-07 | 20-F · 0001185185-26-001294 |
| 2024-01-01 | 2024-12-31 | 42,291,200 | shares | 2026-04-07 | 20-F · 0001185185-26-001294 |
| 2023-01-01 | 2023-12-31 | 21,435,315 | shares | 2026-04-07 | 20-F · 0001185185-26-001294 |
| 2022-01-01 | 2022-12-31 | 100 | shares | 2025-04-28 | 20-F · 0001213900-25-035802 |
Related financial histories
- Anbio Biotechnology: total assets
- Anbio Biotechnology: total liabilities
- Anbio Biotechnology: stockholders equity
- Anbio Biotechnology: cash and cash equivalents
- Anbio Biotechnology: net income or loss
- Anbio Biotechnology: operating cash flow
- Anbio Biotechnology: revenue
- Anbio Biotechnology: financing cash flow
- Anbio Biotechnology: investing cash flow
- Anbio Biotechnology: retained earnings or deficit
- Anbio Biotechnology: diluted weighted-average shares
- Anbio Biotechnology: basic earnings per share
- Anbio Biotechnology: diluted earnings per share
- Anbio Biotechnology: operating income or loss
- Anbio Biotechnology: current assets
- Anbio Biotechnology: current liabilities
- Anbio Biotechnology: current accounts payable
- Anbio Biotechnology: net current accounts receivable
- Anbio Biotechnology: operating expenses
- Anbio Biotechnology: gross profit
- Anbio Biotechnology: cost of revenue
- Anbio Biotechnology: selling, general and administrative expense
- Anbio Biotechnology: research and development expense
Inspect the source
- Entity
- Anbio Biotechnology / CIK 0001982708
- Captured
- 2026-09-21T17:37:37.831Z
- SEC response SHA-256
44b52a5461d6c335c1e589f9567b44eb36b2f2a3a13268a8e5effaac7d49a58b
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001982708.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))